Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
NeuroNova AB Medtronic ICON Clinical Research |
---|---|
Information provided by: | NeuroNova AB |
ClinicalTrials.gov Identifier: | NCT00800501 |
This study is conducted to evaluate the safety and tolerability of the drug product sNN0029, containing the growth factor VEGF165, when administered directly into one of the fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed® II pump. Patients with Amyotrophic Lateral Sclerosis will be enrolled.
Condition | Intervention | Phase |
---|---|---|
Amyotrophic Lateral Sclerosis |
Drug: sNN0029 Drug: Placebo |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A Double-Blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump |
Estimated Enrollment: | 28 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
sNN0029: Experimental |
Drug: sNN0029
Continuous ICV infusion at one of three dose levels
|
Placebo: Placebo Comparator |
Drug: Placebo
Continuous ICV infusion
|
Vascular endothelial growth factor (VEGF) is an endogenous human protein fundamental to the development of the vascular and nervous systems in the body. A role for VEGF in ALS has been suggested from observations in animal models of the disease as well as observations of a dysregulation of VEGF production in patients with ALS.
NeuroNova intends to investigate whether intracerebroventricular administration of VEGF165 in the form of the drug product sNN029 can improve motor function and prolong survival in patients with ALS, and in this first study the safety and tolerability of treatment for 3 months will be evaluated.
Assessments will include:
The secondary objective of this study is:
To explore the effect of ICV administration of sNN0029 on the time course of Amyotrophic Lateral Sclerosis related parameters including:
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Belgium | |
University Hospital Leuven, Department of Neurology | |
Leuven, Belgium, 3000 |
Principal Investigator: | Wim Robberecht, MD PhD | University Hospital Leuven, Department of Neurology |
Responsible Party: | University Hospital Leuven ( Dr Wim Robberecht ) |
Study ID Numbers: | sNN0029-001 |
Study First Received: | November 29, 2008 |
Last Updated: | December 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00800501 |
Health Authority: | Belgium: Institutional Review Board |
ALS VEGF165 Safety |
Intracerebroventricular Infusion Implantable |
Amyotrophic lateral sclerosis Neuromuscular Diseases Spinal Cord Diseases Amyotrophic Lateral Sclerosis Central Nervous System Diseases Lou Gehrig's disease |
Sclerosis Degenerative motor system disease Neurodegenerative Diseases Motor neuron disease Motor Neuron Disease |
Pathologic Processes Nervous System Diseases |